Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 1
1990 1
1991 3
1992 4
1993 4
1994 1
1995 4
1996 5
1997 1
1998 3
1999 8
2000 7
2001 5
2002 4
2003 8
2004 6
2005 4
2006 3
2007 5
2008 5
2009 4
2010 2
2011 5
2012 4
2013 3
2014 5
2015 4
2016 3
2017 2
2018 2
2019 1
2020 4
2021 1
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

119 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Anderson R, Miller LD, Isom S, Chou JW, Pladna KM, Schramm NJ, Ellis LR, Howard DS, Bhave RR, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. Anderson R, et al. Nat Commun. 2022 Mar 30;13(1):1673. doi: 10.1038/s41467-022-29039-4. Nat Commun. 2022. PMID: 35354808 Free PMC article. Clinical Trial.
A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates. ...The secondary outcomes of response (CR + CRi) and median survival were 44% (21/48) and …
A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refra …
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. DeAngelo DJ, et al. Blood. 2022 Feb 24;139(8):1135-1146. doi: 10.1182/blood.2021010721. Blood. 2022. PMID: 34543383 Free article. Clinical Trial.
A phase 1/2 study evaluated the safety, tolerability, and antileukemic activity of uproleselan (5-20 mg/kg) with MEC (mitoxantrone, etoposide, and cytarabine) among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). ...E-selectin lig …
A phase 1/2 study evaluated the safety, tolerability, and antileukemic activity of uproleselan (5-20 mg/kg) with MEC (mitoxantrone, e …
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Seiter K, Feldman EJ, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, Papageorgio C, Weiss M, Kancherla R, Ahmed T. Seiter K, et al. Leukemia. 2001 Jun;15(6):963-70. doi: 10.1038/sj.leu.2402122. Leukemia. 2001. PMID: 11417484 Review.
Traditionally, patients exposed to topoisomerase II inhibitors are reported to develop secondary AML with abnormalities of chromosome 11q23. We evaluated the long-term hematologic toxicity of topoisomerase II-intensive high-dose mitoxantrone-based chemotherapy in 16 …
Traditionally, patients exposed to topoisomerase II inhibitors are reported to develop secondary AML with abnormalities of chromosome …
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation; German Adjuvant Breast Cancer Study Group; University of California, San Francisco. Kröger N, et al. Bone Marrow Transplant. 2003 Dec;32(12):1153-7. doi: 10.1038/sj.bmt.1704291. Bone Marrow Transplant. 2003. PMID: 14647269 Review.
The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) follow …
The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an intern …
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
Kalaycio M, Pohlman B, Elson P, Lichtin A, Hussein M, Tripp B, Andresen S. Kalaycio M, et al. Am J Clin Oncol. 2001 Feb;24(1):58-63. doi: 10.1097/00000421-200102000-00010. Am J Clin Oncol. 2001. PMID: 11232951 Clinical Trial.
Remission induction chemotherapy for acute myelogenous leukemia typically combines cytarabine with an anthracycline or anthracycline derivative. ...Patients older than age 55 years with a diagnosis of either de novo or secondary, untreated acute
Remission induction chemotherapy for acute myelogenous leukemia typically combines cytarabine with an anthracycline or …
Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W. Ho AD, et al. J Clin Oncol. 1988 Feb;6(2):213-7. doi: 10.1200/JCO.1988.6.2.213. J Clin Oncol. 1988. PMID: 3422260
Both mitoxantrone and etoposide have been shown to be active in monotherapy trials of relapsed and refractory acute myelogenous leukemia (AML). ...Two cases of early death within the first 6 weeks of treatment were registered. Thus, the combination of …
Both mitoxantrone and etoposide have been shown to be active in monotherapy trials of relapsed and refractory acute myeloge
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Cheng J, Liao Y, Bin T, OUYang J, Chen S, Chen X, Zou W. Cheng J, et al. Curr Med Res Opin. 2020 Nov;36(11):1807-1812. doi: 10.1080/03007995.2020.1808452. Epub 2020 Sep 29. Curr Med Res Opin. 2020. PMID: 32936052
OBJECTIVE: Acute myeloid leukemia (AML) is a hematopoietic stem cell malignancy and the most common type of leukemia, with the 5-year relative survival rate of 19% in Europe. ...However, the case of secondary chronic myeloid leukemia
OBJECTIVE: Acute myeloid leukemia (AML) is a hematopoietic stem cell malignancy and the most common type of leukemia
Secondary acute lymphoblastic leukemia with t (4;11): report on two cases and review of the literature.
Auxenfants E, Morel P, Lai JL, Sartiaux C, Detourmignies L, Bauters F, Fenaux P. Auxenfants E, et al. Ann Hematol. 1992 Sep;65(3):143-6. doi: 10.1007/BF01695815. Ann Hematol. 1992. PMID: 1391125 Review.
We report two cases of secondary acute lymphoblastic leukemia (ALL) with t (4;11) (q21;q23) translocation occurring after chemotherapy and radiotherapy for a prior cancer. Seven previously published cases of secondary ALL with t (4;11) (q21;q23) are al …
We report two cases of secondary acute lymphoblastic leukemia (ALL) with t (4;11) (q21;q23) translocation occurring aft …
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.
Linassier C, Barin C, Calais G, Letortorec S, Brémond JL, Delain M, Petit A, Georget MT, Cartron G, Raban N, Benboubker L, Leloup R, Binet C, Lamagnère JP, Colombat P. Linassier C, et al. Ann Oncol. 2000 Oct;11(10):1289-94. doi: 10.1023/a:1008375016038. Ann Oncol. 2000. PMID: 11106118 Free article.
Few reports have been published on patients treated with the anthracenedione mitoxantrone which also targets topoisomerase II. We observed 10 cases of such t-AML over a 7-year-period in breast cancer patients treated with mitoxantrone combined with fluorouracil, cyc …
Few reports have been published on patients treated with the anthracenedione mitoxantrone which also targets topoisomerase II. We obs …
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group. Braun T, et al. Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6. Cancer. 2015. PMID: 25845577 Free article.
BACKGROUND: Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and o …
BACKGROUND: Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, parti …
119 results